In a significant development for organ transplantation, two U.S. biotechnology companies, United Therapeutics and ...

KDIGO guideline is the first specifically addressing autosomal dominant polycystic kidney disease (ADPKD) and focuses on some unique aspects of management.

The approval is based on results from the Phase III FLOW trial demonstrating Ozempic reduced the risk of severe kidney outcomes by 24% compared to placebo, including kidney failure, reduction in ...

The US Food and Drug Administration on Tuesday approved Ozempic for adults with type 2 diabetes and chronic kidney disease (CKD). The drug is now indicated specifically to treat kidney failure, ...

The Food and Drug Administration approved Novo Nordisk’s Ozempic as the first GLP-1 treatment option for people with type 2 ...

Ozempic, the drug that was originally approved to treat Type 2 diabetes, has now also been approved by the U.S. Food and Drug ...

Regulators have approved the drug as a treatment for weight loss, Type 2 diabetes and lowering the risk of heart attacks and ...

Ozempic, or semaglutide, can now be used to reduce the risk of worsening kidney disease or kidney failure in adults with type ...

The 2023 EULAR (European League Against Rheumatism) and 2024 Kidney Disease: Improving Global Outcomes (KDIGO) guidelines recommend a minimum of 36 months of IST, including induction and maintenance ...

For technical reasons, the English full text will be published approximately two weeks after the German print edition has been published.

AKD=acute kidney disease. AKI=acute kidney injury ... has been shown to be complementary to KDIGO AKI severity stages. 16 However, determining rate of creatinine production and volume of distribution ...